Maurice Moloney - Revision history

Jonathan Matthews at 14:29, 20 February 2014

2014-02-20T14:29:17Z

Jonathan Matthews at 14:27, 20 February 2014

2014-02-20T14:27:58Z

Jonathan Matthews at 14:14, 20 February 2014

2014-02-20T14:14:52Z

Claire Robinson at 20:28, 26 September 2012

2012-09-26T20:28:57Z

Claire Robinson at 20:10, 26 September 2012

2012-09-26T20:10:48Z

Claire Robinson at 20:09, 26 September 2012

2012-09-26T20:09:18Z

Claire Robinson: /* Prof Joe Cummins */

2012-09-26T20:07:18Z

Prof Joe Cummins

Claire Robinson at 20:02, 26 September 2012

2012-09-26T20:02:38Z

Claire Robinson at 20:02, 26 September 2012

2012-09-26T20:02:26Z

Claire Robinson at 17:08, 29 January 2010

2010-01-29T17:08:26Z

@@ Line 11: / Line 11: @@
 :This industry alignment is perfectly illustrated by Rothamsted itself, which partners up with corporations like Bayer, Syngenta and Dupont. It also has an Institute Director who not only drives a Porsche with a GMO number plate but has a c.v. to match. It is Maurice Moloney’s GM research that lies behind Monsanto’s GM oilseed rape. He is the inventor of more than 300 patents and prior to Rothamsted, he also successfully launched his own GM company in Canada - SemBioSys Genetics Inc., in which Dow Agro Science were investors. This was flagged up by the BBSRC when they appointed Moloney in a press release praising his 'effective translation of research into successful business activity.'<ref>Jonathan Matthews, [http://www.spinwatch.org/index.php/issues/science/item/163-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>
-A picture of Moloney's GMO-labelled Porsche can be seen on the Spinwatch website.<ref>Jonathan Matthews, [http://www.spinwatch.org.uk/-articles-by-category-mainmenu-8/46-gm-industry/5505-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>
+A picture of Moloney's GMO-labelled Porsche can be seen on the Spinwatch website.<ref>Jonathan Matthews, [http://www.spinwatch.org/index.php/issues/science/item/163-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>
 ==Biography==

@@ Line 9: / Line 9: @@
 The director of GMWatch, Jonathan Matthews, wrote in an article for Spinwatch about Rothamsted's industry alignment under Moloney's directorship:
-:This industry alignment is perfectly illustrated by Rothamsted itself, which partners up with corporations like Bayer, Syngenta and Dupont. It also has an Institute Director who not only drives a Porsche with a GMO number plate but has a c.v. to match. It is Maurice Moloney’s GM research that lies behind Monsanto’s GM oilseed rape. He is the inventor of more than 300 patents and prior to Rothamsted, he also successfully launched his own GM company in Canada - SemBioSys Genetics Inc., in which Dow Agro Science were investors. This was flagged up by the BBSRC when they appointed Moloney in a press release praising his 'effective translation of research into successful business activity.'<ref>Jonathan Matthews, [http://www.spinwatch.org.uk/-articles-by-category-mainmenu-8/46-gm-industry/5505-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>
+:This industry alignment is perfectly illustrated by Rothamsted itself, which partners up with corporations like Bayer, Syngenta and Dupont. It also has an Institute Director who not only drives a Porsche with a GMO number plate but has a c.v. to match. It is Maurice Moloney’s GM research that lies behind Monsanto’s GM oilseed rape. He is the inventor of more than 300 patents and prior to Rothamsted, he also successfully launched his own GM company in Canada - SemBioSys Genetics Inc., in which Dow Agro Science were investors. This was flagged up by the BBSRC when they appointed Moloney in a press release praising his 'effective translation of research into successful business activity.'<ref>Jonathan Matthews, [http://www.spinwatch.org/index.php/issues/science/item/163-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>
 A picture of Moloney's GMO-labelled Porsche can be seen on the Spinwatch website.<ref>Jonathan Matthews, [http://www.spinwatch.org.uk/-articles-by-category-mainmenu-8/46-gm-industry/5505-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>

← Older revision		Revision as of 14:14, 20 February 2014
Line 1:		Line 1:
−	Maurice Moloney ~~has been~~ the Director and Chief Executive of [[Rothamsted Research]] ~~since~~ 15 April 2010. He was the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he left on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>	+	Maurice Moloney leads the Food, Health and Life Science Industries Group in CSIRO - Australia's [[Commonwealth Scientific and Industrial Research Organisation]]. Prior to that he was the Director and Chief Executive of [[Rothamsted Research]], between 15 April 2010 and December 2013. He was previously the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he left on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>

	Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>		Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>

← Older revision		Revision as of 20:28, 26 September 2012
Line 4:		Line 4:

	He is a professor at the University of Calgary, where he holds the NSERC (Natural Sciences and Engineering Research Council of Canada)/DowElanco Chair in Plant Biotechnology.<ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>		He is a professor at the University of Calgary, where he holds the NSERC (Natural Sciences and Engineering Research Council of Canada)/DowElanco Chair in Plant Biotechnology.<ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>
		+
		+	==Criticism==
		+
		+	The director of GMWatch, Jonathan Matthews, wrote in an article for Spinwatch about Rothamsted's industry alignment under Moloney's directorship:
		+
		+	:This industry alignment is perfectly illustrated by Rothamsted itself, which partners up with corporations like Bayer, Syngenta and Dupont. It also has an Institute Director who not only drives a Porsche with a GMO number plate but has a c.v. to match. It is Maurice Moloney’s GM research that lies behind Monsanto’s GM oilseed rape. He is the inventor of more than 300 patents and prior to Rothamsted, he also successfully launched his own GM company in Canada - SemBioSys Genetics Inc., in which Dow Agro Science were investors. This was flagged up by the BBSRC when they appointed Moloney in a press release praising his 'effective translation of research into successful business activity.'<ref>Jonathan Matthews, [http://www.spinwatch.org.uk/-articles-by-category-mainmenu-8/46-gm-industry/5505-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>
		+
		+	A picture of Moloney's GMO-labelled Porsche can be seen on the Spinwatch website.<ref>Jonathan Matthews, [http://www.spinwatch.org.uk/-articles-by-category-mainmenu-8/46-gm-industry/5505-science-one-whining-greenies-nil ‘Science one, whining greenies nil’], Spinwatch, 1 Jun 2012, acc 26 Sept 2012</ref>

	==Biography==		==Biography==

@@ Line 3: / Line 3: @@
 Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>
-He is a professor at the University of Calgary, where he holds the NSERC/DowElanco Chair in Plant Biotechnology.<ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>
+He is a professor at the University of Calgary, where he holds the NSERC (Natural Sciences and Engineering Research Council of Canada)/DowElanco Chair in Plant Biotechnology.<ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>
 ==Biography==

← Older revision		Revision as of 20:09, 26 September 2012
Line 1:		Line 1:
−	[[Maurice Moloney~~]] is~~ the Director and Chief Executive of [[Rothamsted Research]]~~, assuming the full duties of his post from~~ 15 April 2010. He was the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he left on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>	+	Maurice Moloney has been the Director and Chief Executive of [[Rothamsted Research]] since 15 April 2010. He was the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he left on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>

	Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>		Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>

@@ Line 19: / Line 19: @@
 Prof Joe Cummins, professor emeritus of genetics at the University of Western Ontario, commented on Moloney's history at SemBioSys and his appointment at Rothamsted:
-:Professor Maurice Moloney and his company SemBioSys have focused on producing pharmaceuticals in the oil crops canola (rapeseed) and safflower. In the early efforts a blood thinning peptide called hirudin was produced in canola and had open field tests in the canola growing area of the province Alberta. Hirudin is extremely toxic if consumed even in small quantities by human s or animals. Such open field tests should not have been allowed as the canola pollen is spread widely producing persistent drug pollution of the food  and feed crop.
+:Professor Maurice Moloney and his company SemBioSys have focused on producing pharmaceuticals in the oil crops canola (rapeseed) and safflower. In the early efforts a blood thinning peptide called hirudin was produced in canola and had open field tests in the canola growing area of the province Alberta. Hirudin is extremely toxic if consumed even in small quantities by humans or animals. Such open field tests should not have been allowed as the canola pollen is spread widely producing persistent drug pollution of the food  and feed crop.
 :Currently  safflower-grown human insulin has been open field tested in the state of Washington in a sagebrush wild area of the state which is the habitat for a number of threatened wild species that can be poisoned by ingesting insulin. It is safe to say that Maurice ... will likely spread the gospel of producing pharmaceuticals in food crops as it is done in Canada. In Canada and the United States open field tests of crop bio pharmaceuticals are undertaken with little or no respect for the environmental consequences of the open field releases. UK can now likely look forward to biopharmacueticals in their food, whether they like it or not!<ref>Prof Joe Cummins in an email to GMWatch editors, January 26, 2010 10:52 am. Reproduced with permission.</ref>

← Older revision		Revision as of 20:02, 26 September 2012
Line 1:		Line 1:
−	[[Maurice Moloney]] is the Director and Chief Executive of [[Rothamsted Research]], assuming the full duties of his post from 15 April 2010. He is the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he left on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>	+	[[Maurice Moloney]] is the Director and Chief Executive of [[Rothamsted Research]], assuming the full duties of his post from 15 April 2010. He was the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he left on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>

	Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>		Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>

← Older revision		Revision as of 17:08, 29 January 2010
Line 1:		Line 1:
−	[[Maurice Moloney]] is the Director and Chief Executive of [[Rothamsted Research]], assuming the full duties of his post from 15 April 2010. He is the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he will leave on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant from canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>	+	[[Maurice Moloney]] is the Director and Chief Executive of [[Rothamsted Research]], assuming the full duties of his post from 15 April 2010. He is the Chief Scientific Officer of [[SemBioSys Genetics]] Inc., a post that he will leave on March 25, 2010, remaining a consultant to SemBioSys.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref><ref>[http://www.realtimetraders.com/Content/CanadianNews.aspx?Node=B1&Id=1179338 SemBioSys Announces Departure Of Chief Scientific Officer Maurice Moloney - Quick Facts], RTT News, 13 Jan 2010, accessed 25 Jan 2010</ref> SemBioSys is a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds).<ref>[http://www.dfait-maeci.gc.ca/canada-europa/france/espace/pdf/SemBioSys-ENG.pdf SemBioSys Genetics Inc. Company Overview], undated document, located on Canadian government Foreign Affairs and International Trade website, accessed 25 Jan 2010</ref> A GM pharma specialist, Moloney worked at SemBioSys on deriving a blood anti-coagulant, hirudin, from GM canola.<ref>G.J.H. van Rooijen, B. Kühnel, V. Kumar, J.-H. Liu, S. Mahmoud, M.M. Moloney, [http://www.actahort.org/members/showpdf?booknrarnr=459_51 FROM FARMING FOR FOOD TO PHARMING FOR PHARMACEUTICALS AND OTHER HIGH VALUE PROTEINS IN CRUCIFERS], ISHS Acta Horticulturae 459: International Symposium Brassica 97, Xth Crucifer Genetics Workshop, accessed 25 Jan 2010 (subscription req'd to access full article)</ref><ref>[http://www.agwest.sk.ca/publications/infosource/inf_jul96.php Using Transgenic Plants to Make Medicines], AgBiotech Infosource: Issue 22 July, 1996, accessed 25 Jan 2010</ref><ref>[http://www.bioline.org.br/request?nl96015 Molecular Farming Yields Novel Products from Canola ], The Agbiotech Bulletin Volume 4 Issue 6 June 1996, accessed Jan 25 2010</ref>

	Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>		Previously, Moloney led the Cell Biology group at [[Calgene]], acquired by [[Monsanto]] in 1997.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref> At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.<ref>[http://www.rothamsted.ac.uk/Research/Centres/PressReleases.php?PRID=82 New Director for Rothamsted Research], BBSRC press release, 14 January 2010</ref>